

Global Anti-Obesity Prescription Drugs Market Growth 2023-2029

<https://marketpublishers.com/r/G321525DAE39EN.html>

Date: February 2023

Pages: 96

Price: US\$ 3,660.00 (Single User License)

ID: G321525DAE39EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Growing demand for obesity is one of the recent trends in the global Anti-Obesity Prescription Drugs market. Moreover, this trend is further anticipated to drive the global Anti-Obesity Prescription Drugs market over the forecast period. Furthermore, growing obesity due to unhealthy food and lifestyle such as intake of drugs due to stress, alcohol leads to growing demand for obesity management resulting in growth of this trend.

LPI (LP Information)' newest research report, the "Anti-Obesity Prescription Drugs Industry Forecast" looks at past sales and reviews total world Anti-Obesity Prescription Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Anti-Obesity Prescription Drugs sales for 2023 through 2029. With Anti-Obesity Prescription Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Anti-Obesity Prescription Drugs industry.

This Insight Report provides a comprehensive analysis of the global Anti-Obesity Prescription Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-Obesity Prescription Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Anti-Obesity Prescription Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-Obesity Prescription Drugs and breaks down the

forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-Obesity Prescription Drugs.

The global Anti-Obesity Prescription Drugs market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Anti-Obesity Prescription Drugs is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Anti-Obesity Prescription Drugs is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Anti-Obesity Prescription Drugs is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Anti-Obesity Prescription Drugs players cover F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s, Arena Pharmaceuticals, Glaxosmithkline, Vivus, Boehringer Ingelheim and Alizyme, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Obesity Prescription Drugs market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Pediatric

Adult

Segmentation by application

Hospitals Pharmacies

Retail Pharmacies

E-commerce

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

F Hoffmann La Roche Ltd

Orexigen Therapeutics

Novo Nordisk A/s

Arena Pharmaceuticals

Glaxosmithkline

Vivus

Boehringer Ingelheim

Alizyme

Key Questions Addressed in this Report

What is the 10-year outlook for the global Anti-Obesity Prescription Drugs market?

What factors are driving Anti-Obesity Prescription Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Anti-Obesity Prescription Drugs market opportunities vary by end market size?

How does Anti-Obesity Prescription Drugs break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Anti-Obesity Prescription Drugs Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for Anti-Obesity Prescription Drugs by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for Anti-Obesity Prescription Drugs by Country/Region, 2018, 2022 & 2029
- 2.2 Anti-Obesity Prescription Drugs Segment by Type
 - 2.2.1 Pediatric
 - 2.2.2 Adult
- 2.3 Anti-Obesity Prescription Drugs Sales by Type
 - 2.3.1 Global Anti-Obesity Prescription Drugs Sales Market Share by Type (2018-2023)
 - 2.3.2 Global Anti-Obesity Prescription Drugs Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global Anti-Obesity Prescription Drugs Sale Price by Type (2018-2023)
- 2.4 Anti-Obesity Prescription Drugs Segment by Application
 - 2.4.1 Hospitals Pharmacies
 - 2.4.2 Retail Pharmacies
 - 2.4.3 E-commerce
- 2.5 Anti-Obesity Prescription Drugs Sales by Application
 - 2.5.1 Global Anti-Obesity Prescription Drugs Sale Market Share by Application (2018-2023)
 - 2.5.2 Global Anti-Obesity Prescription Drugs Revenue and Market Share by Application (2018-2023)
 - 2.5.3 Global Anti-Obesity Prescription Drugs Sale Price by Application (2018-2023)

3 GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS BY COMPANY

3.1 Global Anti-Obesity Prescription Drugs Breakdown Data by Company

3.1.1 Global Anti-Obesity Prescription Drugs Annual Sales by Company (2018-2023)

3.1.2 Global Anti-Obesity Prescription Drugs Sales Market Share by Company (2018-2023)

3.2 Global Anti-Obesity Prescription Drugs Annual Revenue by Company (2018-2023)

3.2.1 Global Anti-Obesity Prescription Drugs Revenue by Company (2018-2023)

3.2.2 Global Anti-Obesity Prescription Drugs Revenue Market Share by Company (2018-2023)

3.3 Global Anti-Obesity Prescription Drugs Sale Price by Company

3.4 Key Manufacturers Anti-Obesity Prescription Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Anti-Obesity Prescription Drugs Product Location Distribution

3.4.2 Players Anti-Obesity Prescription Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR ANTI-OBESITY PRESCRIPTION DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Anti-Obesity Prescription Drugs Market Size by Geographic Region (2018-2023)

4.1.1 Global Anti-Obesity Prescription Drugs Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Anti-Obesity Prescription Drugs Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Anti-Obesity Prescription Drugs Market Size by Country/Region (2018-2023)

4.2.1 Global Anti-Obesity Prescription Drugs Annual Sales by Country/Region (2018-2023)

4.2.2 Global Anti-Obesity Prescription Drugs Annual Revenue by Country/Region (2018-2023)

4.3 Americas Anti-Obesity Prescription Drugs Sales Growth

4.4 APAC Anti-Obesity Prescription Drugs Sales Growth

4.5 Europe Anti-Obesity Prescription Drugs Sales Growth

4.6 Middle East & Africa Anti-Obesity Prescription Drugs Sales Growth

5 AMERICAS

5.1 Americas Anti-Obesity Prescription Drugs Sales by Country

5.1.1 Americas Anti-Obesity Prescription Drugs Sales by Country (2018-2023)

5.1.2 Americas Anti-Obesity Prescription Drugs Revenue by Country (2018-2023)

5.2 Americas Anti-Obesity Prescription Drugs Sales by Type

5.3 Americas Anti-Obesity Prescription Drugs Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Anti-Obesity Prescription Drugs Sales by Region

6.1.1 APAC Anti-Obesity Prescription Drugs Sales by Region (2018-2023)

6.1.2 APAC Anti-Obesity Prescription Drugs Revenue by Region (2018-2023)

6.2 APAC Anti-Obesity Prescription Drugs Sales by Type

6.3 APAC Anti-Obesity Prescription Drugs Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Anti-Obesity Prescription Drugs by Country

7.1.1 Europe Anti-Obesity Prescription Drugs Sales by Country (2018-2023)

7.1.2 Europe Anti-Obesity Prescription Drugs Revenue by Country (2018-2023)

7.2 Europe Anti-Obesity Prescription Drugs Sales by Type

7.3 Europe Anti-Obesity Prescription Drugs Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Anti-Obesity Prescription Drugs by Country

8.1.1 Middle East & Africa Anti-Obesity Prescription Drugs Sales by Country
(2018-2023)

8.1.2 Middle East & Africa Anti-Obesity Prescription Drugs Revenue by Country
(2018-2023)

8.2 Middle East & Africa Anti-Obesity Prescription Drugs Sales by Type

8.3 Middle East & Africa Anti-Obesity Prescription Drugs Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Anti-Obesity Prescription Drugs

10.3 Manufacturing Process Analysis of Anti-Obesity Prescription Drugs

10.4 Industry Chain Structure of Anti-Obesity Prescription Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Anti-Obesity Prescription Drugs Distributors

11.3 Anti-Obesity Prescription Drugs Customer

12 WORLD FORECAST REVIEW FOR ANTI-OBESITY PRESCRIPTION DRUGS BY GEOGRAPHIC REGION

12.1 Global Anti-Obesity Prescription Drugs Market Size Forecast by Region

12.1.1 Global Anti-Obesity Prescription Drugs Forecast by Region (2024-2029)

12.1.2 Global Anti-Obesity Prescription Drugs Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Anti-Obesity Prescription Drugs Forecast by Type

12.7 Global Anti-Obesity Prescription Drugs Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 F Hoffmann La Roche Ltd

13.1.1 F Hoffmann La Roche Ltd Company Information

13.1.2 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolios and Specifications

13.1.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 F Hoffmann La Roche Ltd Main Business Overview

13.1.5 F Hoffmann La Roche Ltd Latest Developments

13.2 Orexigen Therapeutics

13.2.1 Orexigen Therapeutics Company Information

13.2.2 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolios and Specifications

13.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 Orexigen Therapeutics Main Business Overview

13.2.5 Orexigen Therapeutics Latest Developments

13.3 Novo Nordisk A/s

13.3.1 Novo Nordisk A/s Company Information

13.3.2 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolios and Specifications

13.3.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

- 13.3.4 Novo Nordisk A/s Main Business Overview
- 13.3.5 Novo Nordisk A/s Latest Developments
- 13.4 Arena Pharmaceuticals
 - 13.4.1 Arena Pharmaceuticals Company Information
 - 13.4.2 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolios and Specifications
 - 13.4.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.4.4 Arena Pharmaceuticals Main Business Overview
 - 13.4.5 Arena Pharmaceuticals Latest Developments
- 13.5 Glaxosmithkline
 - 13.5.1 Glaxosmithkline Company Information
 - 13.5.2 Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolios and Specifications
 - 13.5.3 Glaxosmithkline Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.5.4 Glaxosmithkline Main Business Overview
 - 13.5.5 Glaxosmithkline Latest Developments
- 13.6 Vivus
 - 13.6.1 Vivus Company Information
 - 13.6.2 Vivus Anti-Obesity Prescription Drugs Product Portfolios and Specifications
 - 13.6.3 Vivus Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.6.4 Vivus Main Business Overview
 - 13.6.5 Vivus Latest Developments
- 13.7 Boehringer Ingelheim
 - 13.7.1 Boehringer Ingelheim Company Information
 - 13.7.2 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolios and Specifications
 - 13.7.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.7.4 Boehringer Ingelheim Main Business Overview
 - 13.7.5 Boehringer Ingelheim Latest Developments
- 13.8 Alizyme
 - 13.8.1 Alizyme Company Information
 - 13.8.2 Alizyme Anti-Obesity Prescription Drugs Product Portfolios and Specifications
 - 13.8.3 Alizyme Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.8.4 Alizyme Main Business Overview

13.8.5 Alizyme Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Anti-Obesity Prescription Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Anti-Obesity Prescription Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Pediatric

Table 4. Major Players of Adult

Table 5. Global Anti-Obesity Prescription Drugs Sales by Type (2018-2023) & (K Units)

Table 6. Global Anti-Obesity Prescription Drugs Sales Market Share by Type (2018-2023)

Table 7. Global Anti-Obesity Prescription Drugs Revenue by Type (2018-2023) & (\$ million)

Table 8. Global Anti-Obesity Prescription Drugs Revenue Market Share by Type (2018-2023)

Table 9. Global Anti-Obesity Prescription Drugs Sale Price by Type (2018-2023) & (US\$/Unit)

Table 10. Global Anti-Obesity Prescription Drugs Sales by Application (2018-2023) & (K Units)

Table 11. Global Anti-Obesity Prescription Drugs Sales Market Share by Application (2018-2023)

Table 12. Global Anti-Obesity Prescription Drugs Revenue by Application (2018-2023)

Table 13. Global Anti-Obesity Prescription Drugs Revenue Market Share by Application (2018-2023)

Table 14. Global Anti-Obesity Prescription Drugs Sale Price by Application (2018-2023) & (US\$/Unit)

Table 15. Global Anti-Obesity Prescription Drugs Sales by Company (2018-2023) & (K Units)

Table 16. Global Anti-Obesity Prescription Drugs Sales Market Share by Company (2018-2023)

Table 17. Global Anti-Obesity Prescription Drugs Revenue by Company (2018-2023) (\$ Millions)

Table 18. Global Anti-Obesity Prescription Drugs Revenue Market Share by Company (2018-2023)

Table 19. Global Anti-Obesity Prescription Drugs Sale Price by Company (2018-2023) & (US\$/Unit)

Table 20. Key Manufacturers Anti-Obesity Prescription Drugs Producing Area

Distribution and Sales Area

Table 21. Players Anti-Obesity Prescription Drugs Products Offered

Table 22. Anti-Obesity Prescription Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 23. New Products and Potential Entrants

Table 24. Mergers & Acquisitions, Expansion

Table 25. Global Anti-Obesity Prescription Drugs Sales by Geographic Region (2018-2023) & (K Units)

Table 26. Global Anti-Obesity Prescription Drugs Sales Market Share Geographic Region (2018-2023)

Table 27. Global Anti-Obesity Prescription Drugs Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 28. Global Anti-Obesity Prescription Drugs Revenue Market Share by Geographic Region (2018-2023)

Table 29. Global Anti-Obesity Prescription Drugs Sales by Country/Region (2018-2023) & (K Units)

Table 30. Global Anti-Obesity Prescription Drugs Sales Market Share by Country/Region (2018-2023)

Table 31. Global Anti-Obesity Prescription Drugs Revenue by Country/Region (2018-2023) & (\$ millions)

Table 32. Global Anti-Obesity Prescription Drugs Revenue Market Share by Country/Region (2018-2023)

Table 33. Americas Anti-Obesity Prescription Drugs Sales by Country (2018-2023) & (K Units)

Table 34. Americas Anti-Obesity Prescription Drugs Sales Market Share by Country (2018-2023)

Table 35. Americas Anti-Obesity Prescription Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 36. Americas Anti-Obesity Prescription Drugs Revenue Market Share by Country (2018-2023)

Table 37. Americas Anti-Obesity Prescription Drugs Sales by Type (2018-2023) & (K Units)

Table 38. Americas Anti-Obesity Prescription Drugs Sales by Application (2018-2023) & (K Units)

Table 39. APAC Anti-Obesity Prescription Drugs Sales by Region (2018-2023) & (K Units)

Table 40. APAC Anti-Obesity Prescription Drugs Sales Market Share by Region (2018-2023)

Table 41. APAC Anti-Obesity Prescription Drugs Revenue by Region (2018-2023) & (\$

Millions)

Table 42. APAC Anti-Obesity Prescription Drugs Revenue Market Share by Region (2018-2023)

Table 43. APAC Anti-Obesity Prescription Drugs Sales by Type (2018-2023) & (K Units)

Table 44. APAC Anti-Obesity Prescription Drugs Sales by Application (2018-2023) & (K Units)

Table 45. Europe Anti-Obesity Prescription Drugs Sales by Country (2018-2023) & (K Units)

Table 46. Europe Anti-Obesity Prescription Drugs Sales Market Share by Country (2018-2023)

Table 47. Europe Anti-Obesity Prescription Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 48. Europe Anti-Obesity Prescription Drugs Revenue Market Share by Country (2018-2023)

Table 49. Europe Anti-Obesity Prescription Drugs Sales by Type (2018-2023) & (K Units)

Table 50. Europe Anti-Obesity Prescription Drugs Sales by Application (2018-2023) & (K Units)

Table 51. Middle East & Africa Anti-Obesity Prescription Drugs Sales by Country (2018-2023) & (K Units)

Table 52. Middle East & Africa Anti-Obesity Prescription Drugs Sales Market Share by Country (2018-2023)

Table 53. Middle East & Africa Anti-Obesity Prescription Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 54. Middle East & Africa Anti-Obesity Prescription Drugs Revenue Market Share by Country (2018-2023)

Table 55. Middle East & Africa Anti-Obesity Prescription Drugs Sales by Type (2018-2023) & (K Units)

Table 56. Middle East & Africa Anti-Obesity Prescription Drugs Sales by Application (2018-2023) & (K Units)

Table 57. Key Market Drivers & Growth Opportunities of Anti-Obesity Prescription Drugs

Table 58. Key Market Challenges & Risks of Anti-Obesity Prescription Drugs

Table 59. Key Industry Trends of Anti-Obesity Prescription Drugs

Table 60. Anti-Obesity Prescription Drugs Raw Material

Table 61. Key Suppliers of Raw Materials

Table 62. Anti-Obesity Prescription Drugs Distributors List

Table 63. Anti-Obesity Prescription Drugs Customer List

Table 64. Global Anti-Obesity Prescription Drugs Sales Forecast by Region (2024-2029) & (K Units)

Table 65. Global Anti-Obesity Prescription Drugs Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 66. Americas Anti-Obesity Prescription Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 67. Americas Anti-Obesity Prescription Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 68. APAC Anti-Obesity Prescription Drugs Sales Forecast by Region (2024-2029) & (K Units)

Table 69. APAC Anti-Obesity Prescription Drugs Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 70. Europe Anti-Obesity Prescription Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 71. Europe Anti-Obesity Prescription Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 72. Middle East & Africa Anti-Obesity Prescription Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 73. Middle East & Africa Anti-Obesity Prescription Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 74. Global Anti-Obesity Prescription Drugs Sales Forecast by Type (2024-2029) & (K Units)

Table 75. Global Anti-Obesity Prescription Drugs Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 76. Global Anti-Obesity Prescription Drugs Sales Forecast by Application (2024-2029) & (K Units)

Table 77. Global Anti-Obesity Prescription Drugs Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 78. F Hoffmann La Roche Ltd Basic Information, Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors

Table 79. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolios and Specifications

Table 80. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 81. F Hoffmann La Roche Ltd Main Business

Table 82. F Hoffmann La Roche Ltd Latest Developments

Table 83. Orexigen Therapeutics Basic Information, Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors

Table 84. Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolios and Specifications

Table 85. Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 86. Orexigen Therapeutics Main Business

Table 87. Orexigen Therapeutics Latest Developments

Table 88. Novo Nordisk A/s Basic Information, Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors

Table 89. Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolios and Specifications

Table 90. Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 91. Novo Nordisk A/s Main Business

Table 92. Novo Nordisk A/s Latest Developments

Table 93. Arena Pharmaceuticals Basic Information, Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors

Table 94. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolios and Specifications

Table 95. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 96. Arena Pharmaceuticals Main Business

Table 97. Arena Pharmaceuticals Latest Developments

Table 98. Glaxosmithkline Basic Information, Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors

Table 99. Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolios and Specifications

Table 100. Glaxosmithkline Anti-Obesity Prescription Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 101. Glaxosmithkline Main Business

Table 102. Glaxosmithkline Latest Developments

Table 103. Vivus Basic Information, Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors

Table 104. Vivus Anti-Obesity Prescription Drugs Product Portfolios and Specifications

Table 105. Vivus Anti-Obesity Prescription Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 106. Vivus Main Business

Table 107. Vivus Latest Developments

Table 108. Boehringer Ingelheim Basic Information, Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors

Table 109. Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolios and Specifications

Table 110. Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 111. Boehringer Ingelheim Main Business

Table 112. Boehringer Ingelheim Latest Developments

Table 113. Alizyme Basic Information, Anti-Obesity Prescription Drugs Manufacturing Base, Sales Area and Its Competitors

Table 114. Alizyme Anti-Obesity Prescription Drugs Product Portfolios and Specifications

Table 115. Alizyme Anti-Obesity Prescription Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 116. Alizyme Main Business

Table 117. Alizyme Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Anti-Obesity Prescription Drugs
- Figure 2. Anti-Obesity Prescription Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Anti-Obesity Prescription Drugs Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Anti-Obesity Prescription Drugs Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Anti-Obesity Prescription Drugs Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Pediatric
- Figure 10. Product Picture of Adult
- Figure 11. Global Anti-Obesity Prescription Drugs Sales Market Share by Type in 2022
- Figure 12. Global Anti-Obesity Prescription Drugs Revenue Market Share by Type (2018-2023)
- Figure 13. Anti-Obesity Prescription Drugs Consumed in Hospitals Pharmacies
- Figure 14. Global Anti-Obesity Prescription Drugs Market: Hospitals Pharmacies (2018-2023) & (K Units)
- Figure 15. Anti-Obesity Prescription Drugs Consumed in Retail Pharmacies
- Figure 16. Global Anti-Obesity Prescription Drugs Market: Retail Pharmacies (2018-2023) & (K Units)
- Figure 17. Anti-Obesity Prescription Drugs Consumed in E-commerce
- Figure 18. Global Anti-Obesity Prescription Drugs Market: E-commerce (2018-2023) & (K Units)
- Figure 19. Global Anti-Obesity Prescription Drugs Sales Market Share by Application (2022)
- Figure 20. Global Anti-Obesity Prescription Drugs Revenue Market Share by Application in 2022
- Figure 21. Anti-Obesity Prescription Drugs Sales Market by Company in 2022 (K Units)
- Figure 22. Global Anti-Obesity Prescription Drugs Sales Market Share by Company in 2022
- Figure 23. Anti-Obesity Prescription Drugs Revenue Market by Company in 2022 (\$ Million)
- Figure 24. Global Anti-Obesity Prescription Drugs Revenue Market Share by Company

in 2022

Figure 25. Global Anti-Obesity Prescription Drugs Sales Market Share by Geographic Region (2018-2023)

Figure 26. Global Anti-Obesity Prescription Drugs Revenue Market Share by Geographic Region in 2022

Figure 27. Americas Anti-Obesity Prescription Drugs Sales 2018-2023 (K Units)

Figure 28. Americas Anti-Obesity Prescription Drugs Revenue 2018-2023 (\$ Millions)

Figure 29. APAC Anti-Obesity Prescription Drugs Sales 2018-2023 (K Units)

Figure 30. APAC Anti-Obesity Prescription Drugs Revenue 2018-2023 (\$ Millions)

Figure 31. Europe Anti-Obesity Prescription Drugs Sales 2018-2023 (K Units)

Figure 32. Europe Anti-Obesity Prescription Drugs Revenue 2018-2023 (\$ Millions)

Figure 33. Middle East & Africa Anti-Obesity Prescription Drugs Sales 2018-2023 (K Units)

Figure 34. Middle East & Africa Anti-Obesity Prescription Drugs Revenue 2018-2023 (\$ Millions)

Figure 35. Americas Anti-Obesity Prescription Drugs Sales Market Share by Country in 2022

Figure 36. Americas Anti-Obesity Prescription Drugs Revenue Market Share by Country in 2022

Figure 37. Americas Anti-Obesity Prescription Drugs Sales Market Share by Type (2018-2023)

Figure 38. Americas Anti-Obesity Prescription Drugs Sales Market Share by Application (2018-2023)

Figure 39. United States Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 40. Canada Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Mexico Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Brazil Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 43. APAC Anti-Obesity Prescription Drugs Sales Market Share by Region in 2022

Figure 44. APAC Anti-Obesity Prescription Drugs Revenue Market Share by Regions in 2022

Figure 45. APAC Anti-Obesity Prescription Drugs Sales Market Share by Type (2018-2023)

Figure 46. APAC Anti-Obesity Prescription Drugs Sales Market Share by Application (2018-2023)

Figure 47. China Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 48. Japan Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 49. South Korea Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 50. Southeast Asia Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 51. India Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 52. Australia Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 53. China Taiwan Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 54. Europe Anti-Obesity Prescription Drugs Sales Market Share by Country in 2022

Figure 55. Europe Anti-Obesity Prescription Drugs Revenue Market Share by Country in 2022

Figure 56. Europe Anti-Obesity Prescription Drugs Sales Market Share by Type (2018-2023)

Figure 57. Europe Anti-Obesity Prescription Drugs Sales Market Share by Application (2018-2023)

Figure 58. Germany Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 59. France Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 60. UK Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 61. Italy Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Russia Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Middle East & Africa Anti-Obesity Prescription Drugs Sales Market Share by Country in 2022

Figure 64. Middle East & Africa Anti-Obesity Prescription Drugs Revenue Market Share by Country in 2022

Figure 65. Middle East & Africa Anti-Obesity Prescription Drugs Sales Market Share by Type (2018-2023)

Figure 66. Middle East & Africa Anti-Obesity Prescription Drugs Sales Market Share by Application (2018-2023)

Figure 67. Egypt Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$

Millions)

Figure 68. South Africa Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 69. Israel Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 70. Turkey Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 71. GCC Country Anti-Obesity Prescription Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 72. Manufacturing Cost Structure Analysis of Anti-Obesity Prescription Drugs in 2022

Figure 73. Manufacturing Process Analysis of Anti-Obesity Prescription Drugs

Figure 74. Industry Chain Structure of Anti-Obesity Prescription Drugs

Figure 75. Channels of Distribution

Figure 76. Global Anti-Obesity Prescription Drugs Sales Market Forecast by Region (2024-2029)

Figure 77. Global Anti-Obesity Prescription Drugs Revenue Market Share Forecast by Region (2024-2029)

Figure 78. Global Anti-Obesity Prescription Drugs Sales Market Share Forecast by Type (2024-2029)

Figure 79. Global Anti-Obesity Prescription Drugs Revenue Market Share Forecast by Type (2024-2029)

Figure 80. Global Anti-Obesity Prescription Drugs Sales Market Share Forecast by Application (2024-2029)

Figure 81. Global Anti-Obesity Prescription Drugs Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Anti-Obesity Prescription Drugs Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G321525DAE39EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G321525DAE39EN.html>